Medtronic Hugo Cleared for General Surgery in U.S.
The FDA expanded Hugo's clearance to upper and lower abdominal soft tissue procedures, entering a field Johnson & Johnson also recently entered.
Updated on Nov. 17, 2026 in Healthcare

The FDA has cleared Medtronic's Hugo robotic surgery system for general surgical procedures, including gallbladder removal, gastric bypass, hernia repair, small bowel resection, and appendectomy. The clearance extends Hugo's earlier December authorization for urologic procedures.
Why it matters
Hugo is the first robotic soft tissue platform from a large medtech company to reach the U.S. market since Intuitive launched da Vinci in 2000, giving hospitals a new option in a field that has long been dominated by a single supplier. The clearance could broaden access to robotic-assisted care for the roughly 3.5 million general surgeries performed annually in the United States.
The cleared procedures cover about 3.5 million annual U.S. surgeries and more than half of U.S. soft tissue procedures each year. Hugo procedure growth globally is running at more than two times the robotic surgery market, and the company projects more than 50,000 procedures by the end of its fiscal year.
The players
Medtronic
A global medical technology company headquartered in Ireland with major U.S. operations, known for its surgical devices, cardiac technologies, and robotic systems.
Johnson & Johnson
A multinational healthcare corporation whose medical technology division competes in the surgical robotics market with its Ottava system.
Stryker
A large U.S.-based medical technology company that makes orthopedic and surgical equipment and is expanding its robotic surgery offerings through distribution agreements.
Intuitive
The company behind the da Vinci surgical robot, which has dominated the robotic soft tissue surgery market in the U.S. since its launch in 2000.
The details
The clearance covers all upper abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia, and small bowel resection, as well as inguinal hernia and appendectomy as lower abdominal procedures. Surgeons can use Medtronic's LigaSure vessel-sealing instrument in robotic cases.
Timeline
December: Hugo received initial FDA clearance for urologic procedures, including prostate removal.
July: Johnson & Johnson received FDA authorization for its Ottava system in general surgery.
Last month: Stryker unveiled an agreement to distribute CMR Surgical's Versius soft tissue robot in the U.S.
Tuesday: Medtronic announced the expanded FDA clearance for Hugo.
End of Medtronic's fiscal year: Hugo is expected to exceed 50,000 procedures globally.
Roadmap
Hugo is the first robotic soft tissue platform from a large medtech company to reach the U.S. market since Intuitive launched da Vinci in 2000. The clearance follows a wave of competitor authorizations, including Johnson & Johnson's Ottava in July, signaling a rapid shift toward multi-vendor competition in soft tissue robotics.
Patients scheduled for gallbladder removal, hernia repair, gastric bypass, or appendectomy in the U.S. may increasingly encounter robotic-assisted options as hospitals add new systems. Hospitals and surgeons gain a second robotic platform to evaluate, which could influence procedure availability and scheduling over time.
The takeaway
The FDA's expanded clearance means robotic-assisted general surgery is moving from a single-supplier market toward multiple competing platforms. Patients discussing surgical options with their physicians may find more robotic choices available as hospitals adopt these systems.
What happens next
Hugo is expected to pass 50,000 global procedures by the end of Medtronic's fiscal year, a milestone the company will be measured against.
Further reading
For more on how the sector is changing, explore Healthcare coverage across U.S. medical technology and hospital markets.






